We recently described a mouse aortocaval fistula model that mimics human AVF maturation, with a distinct maturation phase during which approximately two-thirds of AVF successfully mature and one-third of AVF fail to mature (6) . We use this model to examine the regulation of ECM components during AVF maturation. We hypothesized that during AVF maturation, regulatory and structural components of the ECM have organized temporal expression patterns.
Materials and Methods

Arteriovenous fistula creation
Aortocaval fistulae were created as previously described (6, 7) . In brief, AVF were created in C57BL/6J male mice at age 10 weeks (20-30 g) using a 25 gauge needle to puncture the lateral wall of the aorta, through and through, entering the inferior vena cava caudal to the renal vessels. The lateral puncture site of the aorta was sealed with gentle manual compression of the surrounding tissue until hemostasis achieved, with care taken not to compress the fistula between the aorta and the inferior vena cava. The presence of the AVF was confirmed by direct visualization of pulsatile arterial blood flow in the inferior vena cava (IVC) as well as serial Doppler ultrasound starting on day 1. Each AVF was accompanied by a paired mouse that underwent a sham procedure consisting of midline laparotomy without the AVF creation.
The venous limb of the AVF was analyzed at predetermined time points by carefully removing the abdominal IVC from the point of the fistula cephalad to the hepatic confluence. Samples were taken from baseline (preoperative) mice, as well as postoperative day 1, 3, 7, 21, and 42, each with a paired sham IVC control. Prior to harvest, ultrasound interrogation was performed to determine AVF patency. Occluded AVF at any time point were excluded (6) .
Gene expression microarray analysis
Gene expression in the venous limb of the AVF was compared with that in the IVC of sham mice (day 7; n = 4). RNA was isolated from pooled samples and analyzed for whole genome gene expression using the Mouse Gene 1.0 ST array (Cat. No. 901168; Affymetrix, Santa Clara, California, USA). Samples were hybridized to arrays for 16 h at 45°C. Significant changes between AVF and sham veins in gene expression were determined using a false discovery rate less than 0.05 and a fold change of more than 2.0 or less than -2.0. Significantly increased or decreased expression of gene pathways was analyzed using principle component analysis and pathway enrichment analysis (MetaCore; Thomson Reuters, New York, USA).
RNA extraction and real-time polymerase chain reaction
The venous limb of the fistula (specimens) or the IVC (control) was removed with care taken to avoid surrounding arterial and connective tissue and total RNA isolated using RNeasy Mini Kit with digested DNase I (Qiagen, Valencia, California, USA). RNA quality was confirmed using the 260/280 nm ratio (Nanodrop; Thermo Scientific, Wilmington, Delware, USA). Reverse transcription was performed using SuperScript III First-Strand Synthesis Supermix (Invitrogen; Life Technologies, Carlsbad, California, USA). Real-time PCR was performed using iQ SYBR Green Supermix (Bio-Rad, Hercules, California, USA). Samples were amplified for 35 cycles using the iQ5 Real-Time PCR Detection System (Bio-Rad). Correct target amplification and exclusion of nonspecific amplification was confirmed by 1.5% agarose gel electrophoresis; primer efficiencies were determined by melt curve analysis. Primers used are as listed in Table I . All samples were normalized by GAPDH RNA amplification.
Histology
Venous limbs of AVF and IVC were extracted en bloc after circulatory flushing with PBS followed by 10% formalin. The tissue block was then embedded in paraffin and cut in 5-μm cross-sections. Hematoxylin & eosin (H&E), Masson's Trichrome, and elastic van Gieson (EVG) staining was performed on samples from preoperative as well as day 1 through day 42 AVF.
Antibodies
A mouse monoclonal antibody directed against mouse MMP-2 (Clone: 6E3F8) (ab86607) and rabbit polyclonal antibodies directed against mouse MMP-9 (ab38898), TIMP-1 (ab38978), and osteopontin (OPN, ab8448) were purchased from Abcam (Cambridge, Massachusetts, USA). Antibodies against mouse collagen type I, III, and fibronectin were raised in rabbits and purified as described elsewhere (8, 9) .
Immunohistochemistry
The venous limb of the AVF was analyzed approximately 100 microns cranial to the fistula, that is, between the fistula and renal vessels. Immunohistochemistry was performed using the Dako EnVision TM + Dual Link System-HRP (Dako; Carpinteria, California, USA). For collagen type I, III, and fibronectin, sections were pre-treated with 3.0% hyaluronidase (bovine testicular origin, type I-S; Sigma-Aldrich Co, St. Louis, Missouri, USA) in PBS (pH 7.4) for 30 min at 37˚C. For MMP-2, MMP-9, and TIMP-1, sections were heated in citric acid buffer (pH 6.0) at 100˚C for 10 min using Lab Vision PT Module (Thermo Scientific; Kalamazoo, Missouri, USA). The sections were treated with 0.3% hydrogen peroxide in methanol for 30 min at room temperature to block endogenous peroxidase activity and incubated with 5% normal goat serum in PBS (pH 7.4) containing 0.05% Triton X-100 (T-PBS) for 1 h at room temperature to block non-specific protein binding sites. Sections were then incubated at 4˚C with the primary antibodies diluted at 1:200 (anti-collagen type I, III, and fibronectin), 1:300 (anti-MMP-2), and 1:500 (anti-MMP-9, TIMP-1, and OPN) in T-PBS. After overnight incubation, the sections were incubated with EnVision reagents for 1 h at room temperature and treated with Dako Liquid DAB+ Substrate Chromogen System (Dako) to visualize the reaction products. Finally, the sections were counterstained with Dako Mayer's Hematoxylin (Lillie's Modification) Histological Staining Reagent (Dako).
Relative quantification of histological and IHC staining was performed (MetaMorph; Molecular Devices, LLC, Sunnyvale, California, USA). Each venous limb of AVF sample was compared with its respective sham vein sample of the same postoperative day where applicable and all samples were compared with controls stained simultaneously.
Statistical analysis
All data were analyzed using Prism 6 software (GraphPad Software, Inc, La Jolla, California, USA). Comparison of AVF samples to paired sham samples as well as baseline preoperative samples was made using paired t-test or one-way analysis of variance (ANOVA) with post-hoc analysis using Dunnett's multiple comparisons test where applicable. P values of less than 0.05 were considered significant.
Microarray analysis was performed using hierarchical clustering analysis as well as principle component analysis and pathway enrichment analysis (MetaCore). Significant changes in gene expression of AVF compared with paired sham IVC were determined using a false discovery rate less than 0.05 and a fold change more than 2.0 or less than -2.0.
Results
Compared with preoperative veins, histological analysis of AVF revealed temporal changes in the vessel wall characteristics during the 42-day study period ( Fig. 1A-C ). The fistula thickened over time, compared with the preoperative vein, consistent with AVF maturation (Fig. 1D ). The number of cells in the venous limb increased during AVF maturation compared with control veins (Fig. 1E ). Trichrome staining showed increased collagen and matrix deposition during AVF maturation ( Fig. 1F ). Similarly, elastin deposition was increased compared with control veins later during AVF maturation ( Fig. 1G ). Since day 7 was associated with early AVF thickening ( Fig. 1D ), gene expression changes in the day 7 venous limb were compared with sham veins using microarray analysis. There were 1196 genes with significantly altered expression; 654 genes were increased and 542 genes decreased by twofold or more in the AVF than in veins. The genes with the most highly increased and decreased expression are listed in Table II . Pathway enrichment analysis showed 38 significantly regulated pathways, with metabolism and cell cycle pathways being the pathways with the most highly increased expression (Tab. III).
As AVF maturation is characterized by wall thickening and deposition of ECM ( Fig. 1) , we analyzed the pathway regulating synthesis and secretion of ECM components during AVF maturation; there was significantly increased expression The temporal regulation of mRNA expression of several MMP is summarized in Table VI . Expression of MMP-2 mRNA in the AVF was significantly increased, compared with control veins, at day 7 ( Fig. 2A) . IHC showed increased MMP-2 immunoreactivity ( Fig. 2B ) in both the arterial and venous limbs of the AVF (Fig. 2C) , with increased MMP-2 staining in the endothelium of the venous limb compared with control veins (Fig. 2D) . In contrast, MMP-9 mRNA expression was increased maximally on day 1 compared with control veins (Fig. 3A) . IHC showed increased MMP-9 immunoreactivity (Fig. 3B ) in the venous limb ( Fig. 3C ) compared with control veins (Fig. 3D) .
The temporal regulation of mRNA expression of the TIMP family is summarized in Table VI. Expression of TIMP1 was increased at day 1 and remained elevated until day 21 compared with control veins (Fig. 4A) . IHC showed increased TIMP1 immunoreactivity (Fig. 4B ) diffusely at day 1 (Fig. 4C ) compared with control veins (Fig. 4D) . TIMP2, TIMP3, and TIMP4 expression remained unchanged at early times and increased at day 21, with seven-fold, six-fold, and two-fold increases, respectively, compared with control veins (Tab. VI). Collagens showed increased mRNA expression at day 7 (Tab. VI). Both collagen I and collagen III had increased expression compared with control veins (Figs. 5A, 6A ), although collagen III showed an earlier increase in expression ( Fig. 6A) .
IHC showed increased interstitial deposition of both collagen I and collagen III (Figs. 5B, 6B ). Collagen I deposition was found within the layers of the remodeling vein (Fig. 5C ), whereas collagen III showed strong staining in the adventitia (Fig. 6C) .
Select non-collagenous proteins were also analyzed as summarized in Tab. VI. OPN has been previously shown to have increased expression during early AVF maturation (10); OPN mRNA expression was increased throughout AVF maturation (Fig. 7A) . A significant increase immediately on day 1, with over 40-fold increase in expression relative to control veins, was confirmed with IHC ( Fig. 7B-D) . Fibronectin (Fn) mRNA expression was increased on day 21 (Fig. 8A) ; there was a three-fold increase in Fn protein (Fig. 8B) in AVF compared with control veins (Fig. 8C, D) . Expression of elastin mRNA was increased on days 3 and 7 (Tab. VI), preceding deposition of elastin into the AVF (Fig. 1G) . 
Discussion
The dynamic process of ECM expression, synthesis, secretion, and deposition during AVF venous limb maturation occurs in distinct temporal phases ( Fig. 9 ). Initial ECM degradation occurs early after AVF creation, coincident with early increased expression of MMP and TIMP1. By day 7, there is an increased expression of many collagen subunits as well as changing patterns of MMP expression. By day 21, a later phase is characterized by reduced MMP expression and increased expression of larger structural and non-collagenous matrix proteins. These results show distinct temporal regulation of the ECM components during AVF maturation. The microarray analysis comparing mRNA expression in the AVF with sham IVC was performed on day 7 after surgery. This time point is consistent with generally accepted maximal vessel proliferation during venous adaptation to the arterial circulation. Zwolak et al described maximal endothelial and smooth muscle cell replication at day 7 in a rabbit vein graft model (11) . Castier et al reported that those smooth muscle cells accumulated from the stimulated resident cells and not from circulating progenitor cells (5) . The pathways generated from this data (Tab. III) are consistent with these findings, as the metabolic and cell proliferation pathways were the pathways with the most increased activity at this time point. Our finding of increased cell numbers after day 7 (Fig. 1E ) likely reflects both cell proliferation and cell migration into the AVF.
Increased MMP-2 in the serum of adult human patients has been correlated with AVF maturation (12) . We demonstrate that, during the early phase of ECM breakdown, there is an increased expression of several MMPs (Tab. VI; Fig. 2 ). This increased MMP expression may be required for degradation of the vessel structure to accommodate the structural changes associated with maturation, but these changes must occur without wall weakening and structural failure. Misra et al have demonstrated a two-fold increase in MMP-2 at day 14 and over 50% increase in MMP-9 at day 28 in the venous stenosis in a rat AVF model, suggesting that MMP activity later in AVF maturation may be associated with AVF failure due to stenosis formation (13) . Increased MMP-2 and MMP-9 expression is implicated in vessel wall dilation and structural weakening in both human and murine abdominal aortic aneurysm (AAA) formation (14, 15) . In addition, increased MMP-9 expression in both the aortic wall and serum is associated with ruptured AAA in human patients (16, 17) . The stimulus for this early increase in MMP expression in our study may be secondary to vessel injury from the AVF surgery as well as a normal regulatory maturation process (18, 19) .
Expression of MMP-14 was increased on day 7 by over fivefold in the microarray analysis (Tab. IV). MMP-14 is a membrane-bound protein regulator of other proteins involved in matrix modulation, cell migration, and signaling between the matrix and cells. MMP-14 activates pro-MMP-2 (20), degrades ECM components including collagens and fibronectin (21) , and promotes cell migration via heterodimerization with membrane receptor CD44 (22) . Our data suggest an orderly expression pattern of MMP during AVF maturation that is probably essential for vessel remodeling without wall weakening and degradation, whereas large increases in these proteins may be associated with vessel wall weakening and rupture.
The TIMP family is a group of endogenous specific inhibitors of the MMP. TIMP 1-3 inhibit smooth muscle cell proliferation in human saphenous veins and vein grafts (23) (24) (25) . However, TIMPs are associated with both AVF maturation and AVF failure; TIMP-2 and TIMP-4 are associated with AVF maturation (12, 26) and TIMP-1 and TIMP-2 are associated with AVF failure (27) in human and murine models, respectively. In our mouse model, TIMP1 is the most highly expressed TIMP, with sustained increased expression from days 1 to 21. TIMP1 is thought to be the predominant regulator of the pathological effects of MMP in aneurysmal disease, with an increased MMP:TIMP1 expression ratio associated with aneurysm formation (28, 29) . TIMP1 knockout mice develop larger aneurysms than controls (30) . Our data suggest that TIMP1 may facilitate venous dilatation and AVF remodeling.
We report increased collagen and other structural protein expression and deposition at later time points during AVF maturation. Increased early elastin and fibrillin-1 mRNA expression (Tab. VI) followed by later elastin fragment deposition ( Fig. 1g ) demonstrates orderly venous remodeling that retains structural integrity during venous adaptation to the arterial environment. Although elastin is usually stable with a very long half-life, increased elastin and/or fibrillin-1 expression during AVF adaptation may be a marker of venous "arterialization," for example, loss of venous identity during venous adaptation to the arterial environment (31) . Many of the large matricellular proteins are also actively involved in the regulation of vessel changes in addition to their roles as scaffolds for vessel remodeling. For example, an internal fragment of collagen XVIII is endostatin, a potent angiogenic inhibitor (32) ; fibronectin regulates smooth muscle cells during vascular wall remodeling (33, 34) ; and thrombospondin-2, a potent anti-angiogenic component of the ECM, modulates MMP-2 and MMP-9 activity in endothelial cell ECM (35) .
Several previous reports showing increased MMP and TIMP expression in AVF have focused on the failing fistula (27, (36) (37) (38) ; we report the temporal expression sequence that occurs during successful AVF maturation. Although Kwei et al described early AVF maturation, it is not clear whether the AVF matured successfully or failed subsequent to the early time points examined; in addition, they focused on inflammation and expression of E-selectin and VCAM-1 (4). This group also reported a microarray analysis of the AVF at day 7 and described OPN as the gene with highest expression in the remodeling AVF (10) . Similar to the findings of Abeles et al, the matrix of the AVF is one of the most significantly altered pathways in microarray analysis of AVF maturation (10) . We report the changes in the venous limb and the ECM over the course of AVF maturation, a notable limitation of their study.
We also report a significant increase in OPN that persists throughout AVF maturation. OPN, an ECM-modulating protein that is involved in neointimal hyperplasia formation (39) , increases during venous remodeling (40, 41) . Liaw et al found OPN essential to neointima formation in a rat carotid artery injury model suggesting its function as an initiator of general vascular remodeling (42) . OPN also modulates MMP-2 and MMP-14 suggesting direct involvement of these genes in the remodeling pathway (39, 43) . In addition, Zohar et al described the co-localization of OPN and CD44 (a known receptor for hyaluronan) as a functional complex supporting hyaluronan-mediated mechanisms of matrix changes (44) . Although the role of OPN is not specific to venous remodeling, our data support a major role for OPN in AVF maturation.
Temporal regulation of gene expression is a common paradigm. For example, the Hox genes are expressed along a structural head-to-tail axis (spatial collinearity) as well as in temporal stages (temporal collinearity) in the developing vertebrate (45) . The temporal regulation of gene expression during AVF maturation is poorly described in previous reports, with many reports analyzing only a single time point. Our finding of the expression of regulatory components prior to the structural components allows focus on this earlier time point to find appropriate control points for therapeutic manipulation.
Conclusion
We demonstrate that the expression of ECM components during AVF maturation is a dynamic process that occurs in distinct temporal phases. We believe that these distinct phases allow regulated changes in ECM components to allow venous adaptation to the arterial environment without loss of the vessel's structural integrity.
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